Macroscopic on Site Evaluation (MOLSE) vs Standard Specimen Acquisition of Solid Lesions During EUS-FNB

Not Applicable

• Conditions: Endoscopic Ultrasonography With Tissue Acquisition
• Interventions: Other: MOSE

• Registration Number: NCT04486274
• Lead Sponsor: Istituto Clinico Humanitas

Brief Summary

Endoscopic ultrasonography (EUS) with tissue acquisition (TA) is nowadays a well-established technique for the sampling of solid lesions pancreatic and non-pancreatic lesions. Actually the standard methods to obtain sampling in gastrointestinal (GI) and non-GI solid masses is the fine needle aspiration (FNA) performed by endoscopic ultrasonography (EUS). Its sensitivity, specificity and diagnostic accuracy for malignant cytology are actually reported of 85-95%, 95%-98% and 78-95% respectively. These data could be affected by the presence of cytopathologist in endoscopy room during the tissue sampling. The rapid on-site evaluation (ROSE) has been advocated to significantly increase EUS-FNA accuracy. To overcome this problem fine needle biopsy (FNB) for TA to obtain histological specimens was proposed. These needles allow as the acquisition of an histological specimen than the cytological one with FNA needles. Recently, the need to obtain a histological, instead of a cytological, specimen during EUS has become more urgent and necessary due to innovative oncological treatment options. An acquired histological specimen could avoid the need of a cytopathologist in the endoscopic room, diminishing costs, procedures time, number of passes and reducing the additional costs of a possible repeated EUS-FNA, in case of an inconclusive diagnosis.

With the advent of FNB, the macroscopic on-site evaluation (MOSE) of the specimen by the endosonographer was proposed, resulting in a comparable alternative to ROSE.

Detailed Description

Not available

Study Timeline

• Status Verified: 2020-07
• Study Start: 2020-07-17
• Study First Submitted: 2020-07-17
• Study First Submitted QC: 2020-07-22
• Last Update Submitted: 2020-07-22
• Study First Posted: 2020-07-24
• Last Update Posted: 2020-07-24
• Primary Completion: 2021-07-31
• Study Completion: 2021-07-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 370

Inclusion Criteria

• Age greater than 18, both genders.
• Both in-patient and out-patients.
• Presence of a solid lesion. In the presence of a cystic component, the solid part of the lesion should be more 75% of the total.
• FNB performed by a 22G needle Acquire® (Boston Scientific).
• Tissue acquisition with fanning technique.
• Obtained informed consent.

Exclusion Criteria

• Patients underwent EUS-FNA with or without ROSE
• Patients underwent EUS-FNB plus ROSE.
• Previous biopsy of the lesion with diagnosis of malignancy
• Presence of an uncorrectable coagulopathy as defined by abnormal prothrombin time (PT) or partial thromboplastin time (PTT) that does not normalize after administration of fresh frozen plasma.
• Pregnancy or breast-feeding.
• Patients unable to understand and/or read the consent form.
• Inclusion in other study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
MOSE arm	MOSE	The endoscopist will perform biopsy until a macroscopic visible core (MVC) will be obtained and specimen will be placed in a container (Container A-MOSE). If the needle passes performed are less than 3 (1 or 2 passes) the specimens acquired in the remnant passes to join standard care of 3 passes, according to ESGE guidelines, will be placed in a second container (Container B).
non MOSE arm	MOSE	Three needle passes will be performed for each mass

Primary Outcome Measures

Name	Time	Method
To assess the diagnostic accuracy of EUS-FNB with MOSE vs EUS-FNB alone.	12 Months	Diagnostic accuracy will be measure

Trial Locations

Locations (1)

Gastrointestinal Endoscopy Unit; 🇮🇹 Castellanza, Italy